← Back to guidelines
Pharmacology134 papers

Melanin pigmentation of oral mucosa

Last edited: 4/15/2026

Overview

Melanin pigmentation of the oral mucosa refers to abnormal darkening of oral tissues due to increased melanin production, often observed in conditions like Addison's disease, post-inflammatory hyperpigmentation, or certain drug exposures 1.

Diagnosis

  • Clinical examination is primary, noting the distribution and pattern of pigmentation 1.
  • Biopsy may be considered in atypical presentations to rule out malignancy or other underlying conditions 1.
  • No specific grading system universally accepted; clinical judgment and correlation with systemic findings are crucial 1.
  • Management

  • Address underlying causes: discontinue causative drugs if identified (e.g., hormonal contraceptives like ethinylestradiol and norethindrone) 1.
  • Topical depigmenting agents such as retinoids or corticosteroids may be considered for symptomatic relief 1.
  • Photoprotection measures recommended to prevent further hyperpigmentation 1.
  • Special Populations

  • Pregnancy: Limited data; hormonal changes can exacerbate pigmentation; close monitoring and avoidance of unnecessary medications advised 1.
  • Pediatrics: Rare; typically associated with genetic conditions or post-inflammatory changes; management focuses on underlying causes 1.
  • Elderly: Increased prevalence of underlying systemic diseases; thorough evaluation for associated conditions essential 1.
  • Comorbidities: Conditions like Addison's disease require specific endocrine management to address pigmentation 1.
  • Key Recommendations

  • Identify and discontinue potential drug triggers, particularly hormonal contraceptives, if melasma-like pigmentation is observed (Evidence: Moderate 1).
  • Implement photoprotection strategies including the use of broad-spectrum sunscreens to prevent exacerbation of pigmentation (Evidence: Expert opinion 1).
  • Consider biopsy for atypical presentations to exclude other pathologies (Evidence: Moderate 1).
  • References

    1 Qu Y, Wang S, Xie H, Meng X, Cui B, Xiao Z. Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS). BMC pharmacology & toxicology 2025. link

    Original source

    1. [1]
      Melasma secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).Qu Y, Wang S, Xie H, Meng X, Cui B, Xiao Z BMC pharmacology & toxicology (2025)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG